Cargando…

HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2–3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

OBJECTIVE: To compare changes over 48 weeks in body fat, lipids, Metabolic Syndrome and cardiovascular disease risk between patients randomised 1∶1 to lopinavir/ritonavir (r/LPV) plus raltegravir (RAL) compared to r/LPV plus 2–3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Allison, Moore, Cecilia L., Mallon, Patrick W. G., Hoy, Jennifer F., Emery, Sean, Belloso, Waldo H., Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3813715/ https://www.ncbi.nlm.nih.gov/pubmed/24204757 http://dx.doi.org/10.1371/journal.pone.0077138

Ejemplares similares

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
por: Martin, Allison, et al.
Publicado: (2013)

HRQoL improves in treatment-naïve HIV-1 subjects initiated on lopinavir/ritonavir (LPV/r) with raltegravir (RAL) or tenofovir/emtricitabine (TDF/FTC)
por: Baran, RW, et al.
Publicado: (2010)

Efficacy and safety of lopinavir/ritonavir (LPV/r) in antiretroviral-experienced subjects infected with different subtypes of HIV-1
por: Maroldo, L, et al.
Publicado: (2010)

CSF LPV concentrations and viral load in viral suppressed patients on LPV/r monotherapy given once daily
por: Tiraboschi, Juan, et al.
Publicado: (2014)

Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
por: Deng, Lisi, et al.
Publicado: (2020)

Current Efavirenz (EFV) or Ritonavir-Boosted Lopinavir (LPV/r) Use Correlates with Elevate Markers of Atherosclerosis in HIV-Infected Subjects in Addis Ababa, Ethiopia
por: Gleason, Rudolph L., et al.
Publicado: (2015)

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults
por: Orkin, C, et al.
Publicado: (2010)

A comparison of the FDA TLOVR and FDA Snapshot algorithms based on studies evaluating once-daily vs. twice daily lopinavir/ritonavir (LPV/r) regimens
por: Qaqish, R, et al.
Publicado: (2010)

144-week outcomes of lopinavir/ritonavir (LPV/r)-based first-line ART in 1,409 HIV-infected patients: data from the German STAR/STELLA cohort
por: Wolf, Eva, et al.
Publicado: (2014)

Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients
por: Berno, Giulia, et al.
Publicado: (2014)

Status of coupling compensation for the LPv3 optics in 1995
por: Verdier, A
Publicado: (1995)

A deterministic approach for design of supervisory control of LPV systems with delay
por: Zahid, Ch. Nauman, et al.
Publicado: (2021)

Self-Scheduled LPV Control of Asymmetric Variable-Span Morphing UAV
por: Lee, Jihoon, et al.
Publicado: (2023)

LPV modeling of nonlinear systems: A multi‐path feedback linearization approach
por: Abbas, Hossam S., et al.
Publicado: (2021)

Combination of long-acting HIV fusion inhibitor albuvirtide and LPV/r showed potent efficacy in HIV-1 patients
por: Zhang, Hongwei, et al.
Publicado: (2016)

Understanding the acceptability and adherence to paediatric antiretroviral treatment in the new formulation of pellets (LPV/r): the protocol of a realist evaluation
por: Nebot Giralt, Ariadna, et al.
Publicado: (2017)

LPV Control for the Full Region Operation of a Wind Turbine Integrated with Synchronous Generator
por: Cao, Guoyan, et al.
Publicado: (2015)

Understanding acceptance of and adherence to a new formulation of paediatric antiretroviral treatment in the form of pellets (LPV/r)—A realist evaluation
por: Nebot Giralt, Ariadna, et al.
Publicado: (2019)

Comprehensive evaluation of the efficacy and safety of LPV/r drugs in the treatment of SARS and MERS to provide potential treatment options for COVID-19
por: Wu, Liusheng, et al.
Publicado: (2021)

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial
por: Hakim, James G, et al.
Publicado: (2018)

Randomized trial of DRV/r or LPV/r QD monotherapy vs maintaining a PI/r-based antiretroviral regimen in persons with suppressed HIV replication
por: Pinnetti, Carmela, et al.
Publicado: (2014)

An LPV Adaptive Observer for Updating a Map Applied to an MAF Sensor in a Diesel Engine
por: Liu, Zhiyuan, et al.
Publicado: (2015)

First-line therapy with LPV/r vs NVP and 2 NRTIs in a developing country: W144 of a randomized trial
por: Clumeck, Nathan, et al.
Publicado: (2014)

Pursuing use of optimal formulations for paediatric HIV epidemic control – a look at the use of LPV/r oral pellets and oral granules
por: Malati, Christine Y, et al.
Publicado: (2019)

Evolution of Framingham cardiovascular risk score in HIV-infected patients initiating EFV- and LPV/r-based HAART in a Latin American cohort
por: Cecchini, Diego, et al.
Publicado: (2014)

LPV Control and Virtual-Sensor-Based Fault Tolerant Strategies for a Three-Axis Gimbal System
por: Medero, Ariel, et al.
Publicado: (2022)

Pilot, Randomized Study Assessing Safety, Tolerability and Efficacy of Simplified LPV/r Maintenance Therapy in HIV Patients on the 1(st) PI-Based Regimen
por: Cahn, Pedro, et al.
Publicado: (2011)

A new LPV modeling approach using PCA-based parameter set mapping to design a PSS
por: Jabali, Mohammad B. Abolhasani, et al.
Publicado: (2017)

2491. Virologic Response of Switching Tenofovir Disoproxil Fumarate (TDF)-Based Regimen to Abacavir (ABC)-Based Regimen vs. Lopinavir/Ritonavir(LPV/r) Plus Lamivudine(3TC) in HIV-Infected Patients with TDF-Induced Nephrotoxicity at 24 Weeks: A Prospective, Open-Label, Randomized, Controlled Trial
por: Songumpai, Nopporn, et al.
Publicado: (2019)

Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults
por: Gatell, Josép M, et al.
Publicado: (2014)

Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice
por: Tanaka, Tomokazu, et al.
Publicado: (2018)

Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

Correction: Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
por: Amin, Janaki, et al.
Publicado: (2015)

H(∞)/LPV controller design for an active anti-roll bar system of heavy vehicles using parameter dependent weighting functions
por: Vu, Van Tan, et al.
Publicado: (2019)

Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China
por: Huang, Xiaojie, et al.
Publicado: (2019)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020)

Combining New Non-Nucleoside Reverse Transcriptase Inhibitors (RTIs) with AZT Results in Strong Synergism against Multi-RTI-Resistant HIV-1 Strains
por: Yu, Fei, et al.
Publicado: (2018)

Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0gppfp64dso6kufjifuhqi47ra